STOCK TITAN

Enanta Pharmaceuticals Inc Stock Price, News & Analysis

ENTA Nasdaq

Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.

Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology leader focused on discovering novel small molecule drugs for viral infections and liver diseases. This dedicated news hub provides investors and industry observers with essential updates on the company's research advancements, regulatory milestones, and strategic initiatives.

Access authoritative coverage of ENTA's progress in developing direct-acting antiviral therapies and host-targeted approaches. The repository includes press releases related to clinical trial outcomes, partnership announcements with pharmaceutical collaborators, and updates on pipeline candidates targeting conditions like RSV and NASH.

Key updates feature developments in ENTA's chemistry-driven drug discovery platform, intellectual property achievements, and financial performance reports. All content is curated to support informed analysis of the company's position in the competitive antiviral therapeutics market.

Bookmark this page for streamlined access to verified ENTA developments. Check regularly for updates on FDA interactions, scientific publications, and partnership-driven commercialization efforts that shape the company's growth strategy.

Rhea-AI Summary

Enanta (NASDAQ:ENTA) will present clinical data for two oral RSV candidates, zelicapavir (EDP-938) and EDP-323, at IDWeek 2025 held October 19–22, 2025 in Atlanta and virtually. Zelicapavir has a rapid-fire talk and a poster on October 20 reporting shortened RSV symptom duration in a randomized, double-blind, placebo-controlled pediatric trial (children 28 days–36 months). EDP-323 has an oral presentation on October 20 plus a poster on October 22 reporting rapid reductions in RSV symptoms and viral load after human viral challenge. Posters will be posted on the conference platform and the company website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences
-
Rhea-AI Summary

Enanta (NASDAQ:ENTA) announced on October 2, 2025 the closing of an upsized underwritten public offering of 7,475,000 shares of common stock at $10.00 per share, including 975,000 shares sold pursuant to full exercise of the underwriters’ option. Gross proceeds to Enanta were $74.75 million before underwriting discounts, commissions and offering expenses. All shares were offered by Enanta. Net proceeds will be used, together with existing cash and investments, to fund clinical trials, research and development, working capital and general corporate purposes. J.P. Morgan, Jefferies and Evercore ISI acted as joint book‑running managers. The offering was made under a Form S‑3 shelf registration effective February 8, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company, has announced the pricing of an upsized public offering of 6.5 million shares of common stock at $10.00 per share. The offering is expected to generate gross proceeds of $65.0 million before deducting expenses.

The company has granted underwriters a 30-day option to purchase up to an additional 975,000 shares at the public offering price. J.P. Morgan, Jefferies, and Evercore ISI are serving as joint book-running managers. The offering, made under a shelf registration statement, is expected to close on October 2, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.04%
Tags
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company, has announced a proposed public offering of common stock worth $50.0 million. The company will also grant underwriters a 30-day option to purchase up to an additional $7.5 million of shares at the public offering price, less underwriting discounts and commissions.

The offering will be managed jointly by J.P. Morgan, Jefferies, and Evercore ISI as book-running managers. The offering is being made through a shelf registration statement on Form S-3 that became effective on February 8, 2024. The completion of the offering is subject to market and other conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.04%
Tags
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) announced positive topline results from its Phase 2b RSVHR study of zelicapavir, a novel N-protein inhibitor for treating Respiratory Syncytial Virus (RSV) in high-risk adults. The study demonstrated a 6.7-day improvement in symptom resolution for patients with COPD, CHF, or age ≥75 (HR3 population).

Key findings include a lower hospitalization rate in the zelicapavir group (1.7%) versus placebo (5.0%), and a 4-5 day faster median time to undetectable viral load. The drug showed statistically significant improvement in Patient Global Impression of Severity scores and demonstrated a favorable safety profile. The study enrolled 186 subjects, with 121 receiving zelicapavir and 65 receiving placebo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
91.9%
Tags
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) has announced an upcoming conference call and webcast scheduled for Monday, September 29 at 8:30 a.m. ET. The biotechnology company will present topline results from its Phase 2b RSVHR study evaluating zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults.

The live webcast will be accessible through the investors section of Enanta's website under "Events & Presentations". Participants joining by phone are encouraged to register at least 15 minutes before the call to receive dial-in information. The webcast recording will remain available on the company's website for approximately 30 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences clinical trial
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced the passing of its long-serving Chief Financial and Administrative Officer, Paul J. Mellett Jr., who had been with the company since 2003. During his tenure, Mellett played a pivotal role in establishing the company's finance department and led Enanta's IPO in 2013.

Mellett was instrumental in forging strategic partnerships, notably the 2006 collaboration with Abbott (now AbbVie) that led to the development of VIEKIRA PAK® and MAVYRET®/MAVIRET® for hepatitis C treatment, which have cured over one million patients globally. The company has appointed Harry R. Trout, III as interim principal financial officer and Kathleen S. Capps, CPA, as interim principal accounting officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases, has announced its participation in three major investor conferences in September 2025.

Management will present at the Cantor Global Healthcare Conference (September 3), H.C. Wainwright Global Investment Conference (September 9), and Baird Global Healthcare Conference (September 10). All presentations will be available via live webcast on the company's website, with replays archived for at least 30 days.

[]
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
conferences
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) has filed a patent infringement lawsuit against Pfizer in the Unified Patent Court (UPC) of the European Union. The lawsuit concerns European Patent No. EP 4 051 265, which relates to coronavirus protease inhibitors used in Pfizer's COVID-19 antiviral medication, Paxlovid™.

The legal action targets Pfizer's activities across 18 EU countries participating in the UPC. The patent in question is based on Enanta's July 2020 application and is the European counterpart to U.S. Patent No. 11,358,953, which is already involved in ongoing U.S. litigation between the companies. Under UPC procedures, a hearing is expected within a 12-month timeframe, with a decision following weeks after.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
none
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q3 2025 financial results, with total revenue of $18.3 million from royalties on AbbVie's HCV regimen MAVYRET®/MAVIRET®. The company posted a net loss of $18.3 million ($0.85 per share), improving from a $22.7 million loss in Q3 2024.

Key pipeline developments include: completion of enrollment in the RSVHR Phase 2 trial of zelicapavir for RSV treatment with topline data expected in September, ongoing IND-enabling studies for EPS-1421 (KIT inhibitor) for urticaria treatment, and progress toward selecting a STAT6 development candidate in 2H 2025. The company maintains a strong financial position with $204.1 million in cash and marketable securities, projected to fund operations into fiscal 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags

FAQ

What is the current stock price of Enanta Pharmaceuticals (ENTA)?

The current stock price of Enanta Pharmaceuticals (ENTA) is $11.02 as of October 10, 2025.

What is the market cap of Enanta Pharmaceuticals (ENTA)?

The market cap of Enanta Pharmaceuticals (ENTA) is approximately 330.7M.
Enanta Pharmaceuticals Inc

Nasdaq:ENTA

ENTA Rankings

ENTA Stock Data

330.65M
26.43M
6.63%
86.53%
13.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
WATERTOWN